News for BCLI Stock

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update BrainStorm Issues 2024 Letter to Shareholders BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update BCLI Update - Progress Supports Our 10x Plus Value Range Potential BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS BrainStorm Cell Therapeutics to Provide Update on NurOwn Program BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments BrainStorm Issues 2023 Letter to Shareholders BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn® for the Treatment of ALS BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS BrainStorm Cell Therapeutics Stock Trading Halted Today BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023 BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023 BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update BrainStorm to Announce Second Quarter Results and Provide a Corporate Update BrainStorm Announces Presentations at June 2022 Scientific Conferences BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting BrainStorm Announces Upcoming Scientific Conference Presentations BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn® BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022 FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021 BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program BrainStorm Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate Update BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS BrainStorm Issues 2020 Letter to Shareholders BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study BrainStorm Announces NurOwn® Expanded Access Program BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn® BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Outcomes at the Virtual New York Stem Cell Foundation Conference BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Corporate Update BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting BrainStorm Appoints William K. White as Senior Vice President, Head of Market Access & Pricing Brainstorm Announces Grant of a New Japanese Patent for NurOwn® BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS) BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn® Mechanism in ALS, Progressive MS and Alzheimer's Disease BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS